...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>癌と化学療法 >Combination therapy of fluoropyrimidine (TS-1) administration and selective intra-arterial cisplatin infusion for tongue carcinoma--a case report
【24h】

Combination therapy of fluoropyrimidine (TS-1) administration and selective intra-arterial cisplatin infusion for tongue carcinoma--a case report

机译：氟嘧啶（TS-1）联合选择性动脉内顺铂输注治疗舌癌的联合治疗－病例报告

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A 64-year-old male with primary squamous cell carcinoma of the tongue (T3N0M0) was treated with the novel fluoropyrimidine oral anticancer drug TS-1 and selective intra-arterial infusion of CDDP. His past history revealed pulmonary emphysema as a complication. Since his pulmonary function was reduced and it would have been difficult to perform surgery under general anesthesia, we started administration of TS-1 (100 mg/day) first and added selective arterial infusion of CDDP (5 mg/day) after one week of TS-1. On day 8 of TS-1 administration (day 2 of arterial infusion), the tumor had shrunk considerably, and on day 15 of TS-1 administration (day 9 of arterial infusion) the tumor had almost completely disappeared. Nausea and vomiting developed as adverse effects on day 20 of TS-1 administration (day 14 of arterial infusion), and administration of the anticancer drugs was stopped. Nutrition management and an antiemetic agent were started by intravenous drip infusion, and the adverse effects improved one week after administration was stopped. By the 5th week after the start of treatment, the tumor had disappeared macroscopically, and a CR had been achieved. Interstitial radiotherapy was performed as supplemental therapy, and as of this writing, September 3, 2002, 16 months after the start of treatment, the patient is being followed on an outpatient basis. His course has been favorable and recurrence-free. Although there were some slight adverse reactions, they were relatively mild, and since sufficient efficacy was observed, oral TS-1 plus selective intra-arterial CDDP therapy was concluded to be an effective method of treatment for patients with a past medical history making their general condition unfavorable.
机译：用新型氟嘧啶口服抗癌药TS-1和CDDP的选择性动脉内输注治疗了64岁男性原发性舌鳞状细胞癌（T3N0M0）。他的既往史显示肺气肿是一种并发症。由于他的肺功能下降并且在全身麻醉下很难进行手术，因此我们首先开始使用TS-1（100毫克/天），并在一周的麻醉后增加CDDP的选择性动脉输注（5毫克/天）。 TS-1。在施用TS-1的第8天（动脉输注的第2天），肿瘤明显缩小，并且在施用TS-1的第15天（动脉输注的第9天），肿瘤几乎完全消失。在TS-1给药的第20天（动脉输注的第14天），恶心和呕吐发展为不良反应，并且停止了抗癌药物的给药。通过静脉滴注开始营养管理和止吐药，停药一周后不良反应得到改善。在开始治疗后的第5周，肿瘤在肉眼上消失了，并且达到了CR。间质放疗作为补充疗法进行，截至撰写本文时（2002年9月3日），即治疗开始后的16个月，正在门诊对患者进行随访。他的病情一直良好且无复发。尽管有一些轻微的不良反应，但它们相对较轻，并且由于观察到足够的疗效，因此口服TS-1加选择性动脉内CDDP治疗被认为是治疗既往病史的患者的有效方法。条件不利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号